Investor Overview

Investor Presentation
Financial News
Aug 4, 2020

Further advances in recurrent glioblastoma program including submission of End of Phase 2 (“EOP2”) meeting package for MDNA55 EOP2 meeting scheduled for 29th September, 2020 with FDA input...

Jun 11, 2020

Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA) (OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and...

Stock Quote
Stock Chart
Upcoming Events
No events to display
Investor Contact
For more investor information, Please contact:
Elizabeth Williams, Chief Financial Officer
Email Alerts
* Required Fields